Cabozantinib(cas: 849217-68-1)

Cabozantinib is an oral multi-target tyrosine kinase inhibitor, marketed under the brand names Cabometyx and Cometriq. Its core characteristic is the ability to simultaneously inhibit multiple targets, including VEGFR, MET, RET, AXL, among others, which play key roles in tumor growth, angiogenesis, metastasis, and drug resistance. This “broad-spectrum” property enables it to demonstrate efficacy in the treatment of various cancers.

I. Currently Approved Major Clinical Applications

1. Renal Cell Carcinoma
   · First-line treatment: Combined with nivolumab for advanced renal cell carcinoma as a first-line therapy. This is currently one of the standard regimens, significantly outperforming sunitinib monotherapy.
   · Second-line treatment: For patients with advanced renal cell carcinoma who have previously failed anti-angiogenic targeted therapies (such as sunitinib, pazopanib, etc.).

2. Hepatocellular Carcinoma
   · Second-line treatment: For patients with advanced hepatocellular carcinoma who have previously failed sorafenib treatment. Clinical studies have shown that it can extend overall survival and improve progression-free survival.

3. Differentiated Thyroid Cancer
   · Treatment of advanced or metastatic DTC: For patients with locally advanced or metastatic differentiated thyroid cancer who have failed prior treatments (such as radioactive iodine therapy) and experienced disease progression.

4. Second-line Treatment for Hepatocellular Carcinoma
   · In specific regions (e.g., China), it has also been approved for the treatment of hepatocellular carcinoma patients who have previously received sorafenib.

II. Promising Applications in Clinical Research (Some with Conditional Approval or in Advanced Research Stages)

1. Radioiodine-Refractory Differentiated Thyroid Cancer
   · Cabozantinib is an important treatment option for patients with advanced thyroid cancer who are no longer sensitive to radioactive iodine therapy.

2. Advanced Prostate Cancer
   · In patients with metastatic castration-resistant prostate cancer harboring specific gene mutations (e.g., BRCA), cabozantinib combined with immunotherapies such as atezolizumab has shown some promise, though it is not yet a global standard therapy.

3. Non-Small Cell Lung Cancer
   · For patients with advanced NSCLC harboring RET gene fusions, cabozantinib was one of the early effective RET inhibitors. However, with the advent of more selective and less toxic RET inhibitors (such as selpercatinib and pralsetinib), its use has largely been superseded.
   · It has also been studied in patients with other specific mutations (e.g., MET amplification or exon 14 skipping mutations), but more specific drugs are also available.

4. Bone Metastasis Control
   · Due to its unique mechanism of action (inhibiting MET and VEGFR2), cabozantinib has shown special advantages in controlling bone metastases of various solid tumors (e.g., prostate cancer, breast cancer, RCC), significantly reducing bone-related events.

III. Administration and Dosage
· Formulation: Primarily available as tablets.
· Common Dosage: The recommended dose for treating RCC and HCC is typically 60 mg once daily (taken on an empty stomach, with no food consumed at least 1 hour before and after administration).
· Dose Adjustment: Due to its side effects, dose adjustments (e.g., reduction to 40 mg or 20 mg once daily) are often required in clinical practice based on patient tolerance.

IV. Major Side Effects and Management
Cabozantinib has a broad range of side effects associated with its multi-target inhibition properties, requiring close monitoring and management:
· Common Side Effects: Diarrhea, fatigue, nausea, decreased appetite, hand-foot skin reactions, hypertension, weight loss, stomatitis, etc.
· Serious Side Effects:
· Bleeding: May cause severe or even fatal hemorrhage.
· Perforation and Fistula: Gastrointestinal perforation or fistula formation.
· Thrombotic Events: Arterial and venous thromboembolism.
· Hypertensive Crisis: Regular blood pressure monitoring is required.
· Hepatotoxicity: May lead to liver injury, requiring regular liver function tests.
· Proteinuria: Urinalysis is necessary.
· Osteonecrosis of the Jaw: Increased risk during dental procedures while on medication.

Summary of Key Points

1. Core Role: Cabozantinib is an important drug for first-line combination therapy in renal cancer and second-line treatment in liver cancer, as well as a key option for refractory thyroid cancer.

2. Broad-Spectrum Property: Due to its multi-target action, it holds unique value in controlling bone metastases and various solid tumors, though this also leads to a broader spectrum of side effects.

3. Personalized Treatment: A comprehensive assessment of the patient’s physical condition, tumor type, and genetic characteristics is required before use. Close side effect monitoring and dose management are essential during treatment.

4. Research Directions: Its combination with immune checkpoint inhibitors (e.g., PD-1 antibodies) is a current research focus in the treatment of many cancers.

V. Product Information
Cabozantinib is an oral multi-target tyrosine kinase inhibitor. For product details and pricing, please click “Contact Us.”